Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PF-06647263||PF06647263|PF 06647263||PF-06647263 is an antibody-drug conjugate consisting of an anti-Ephrin-A4 (EFNA4) monoclonal antibody linked to the drug calicheamicin, which may result in tumor growth inhibition (PMID: 26015513, PMID: 30680712).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||PF-06647263||Phase I||Actionable||In a Phase I trial, PF-06647263 treatment demonstrated safety in patients with advanced solid tumors, and resulted in an objective response rate of 10.4% (5/48, 5 partial responses), with an additional 20 patients achieved stable disease (PMID: 30680712; NCT02078752).||30680712|
|Unknown unknown||ovarian cancer||not applicable||PF-06647263||Case Reports/Case Series||Actionable||In a Phase I trial, PF-06647263 treatment resulted in 1 partial response and 9 stable disease in patients with ovarian cancer (n=16) (PMID: 30680712; NCT02078752).||30680712|
|Unknown unknown||peritoneum cancer||not applicable||PF-06647263||Case Reports/Case Series||Actionable||In a Phase I trial, PF-06647263 treatment resulted in a partial response in a patient with peritoneum cancer (PMID: 30680712; NCT02078752).||30680712|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02078752||Phase I||PF-06647263||A Study Of PF-06647263 In Patients With Advanced Solid Tumors||Terminated||USA||0|